This inventor holds 2 USPTO granted patents. Top assignee: Megmilk Snow Brand Co., Ltd.. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Innovations of Katsumi Imaizumi in Anti-Fatty Liver Agents
Introduction
Katsumi Imaizumi is a notable inventor based in Fukuoka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-fatty liver agents. With a total of two patents to his name, Imaizumi's work focuses on innovative solutions for treating fatty liver conditions.
Latest Patents
Imaizumi's latest patents include an anti-fatty liver agent that contains a cell and/or a culture of lactic acid bacteria as an active ingredient. This invention provides a pharmaceutical agent with anti-fatty liver activity, as well as beverages and foods that incorporate this beneficial component. Additionally, he has developed methods for treating fatty liver in subjects by administering a cell and/or a culture of lactic acid bacteria. Another patent discloses an anti-fatty liver agent comprising a cell and/or a culture obtained by culturing a specific lactic acid bacterium, further emphasizing his commitment to addressing this health issue.
Career Highlights
Katsumi Imaizumi is currently associated with Megmilk Snow Brand Co., Ltd., where he continues to innovate in the field of health and nutrition. His work has garnered attention for its potential impact on public health, particularly in combating fatty liver disease.
Collaborations
Imaizumi collaborates with esteemed colleagues such as Hiroshi Kawakami and Hiroaki Matsuyama. Their combined expertise contributes to the advancement of research and development in their field.
Conclusion
Katsumi Imaizumi's contributions to the development of anti-fatty liver agents highlight his innovative spirit and dedication to improving health outcomes. His patents reflect a significant step forward in the treatment of fatty liver conditions, showcasing the importance of research in this area.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile